Market Overview

Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?


In a report published Monday, Citigroup analyst Liav Abraham hypothesized that Teva Pharmaceutical Industries Ltd (NYSE: TEVA) recent hire of Timothy Wright as Head of Business Development suggests that a "material, potentially transformative transaction is not off the table."

Abraham noted that Wright is considered well connected in the pharmaceutical industry and was well regarded at his previous executive role at Covidien. The hiring "augments" the company's capabilities and connections on the branded side of the business and follows the appointment of generics industry veteran Siggi Olafsson in mid-2014.

The analyst said that his "core tenet" of his "constructive stance" on Teva is supported by a floor earnings per share of $5, undervalued pipeline potential and the potential for greater cost efficiencies, inorganic growth (to diversify away from Copaxone) and generate near-term top and bottom line growth and multiple expansion.

Abraham also noted that the company's balance sheet is under-levered with its debt to EBITDA ratio at less than two. As such, the company has the capacity to increase its balance sheet leverage by more than $15 billion of debt, but any potential material transaction would require "significant integration" along with cost cutting initiatives, executing on synergies and capacity rationalization.

Shares remain Buy rated with a $70 price target.

Latest Ratings for TEVA

Nov 2020BMO CapitalMaintainsMarket Perform
Aug 2020BarclaysUpgradesUnderweightEqual-Weight
Aug 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Citigroup Liav Abraham Siggi Olafsson Teva Pharmaceutical Timothy Wright VocidienAnalyst Color Analyst Ratings

Latest Ratings

CAMTStifelInitiates Coverage On19.0
ELMDNorthland Capital MarketsInitiates Coverage On15.0
DKNGUBSInitiates Coverage On52.0
DIODTruist SecuritiesInitiates Coverage On84.0
TGTArgus ResearchUpgrades205.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at